57
Participants
Start Date
March 3, 2020
Primary Completion Date
October 10, 2023
Study Completion Date
October 10, 2023
Brazikumab Maintenance Dose
Completers in the lead-in study D5272C00001 (Legacy #3151-201-008) will receive a maintenance dose of brazikumab administered subcutaneously every 4 weeks up to Week 52 (Group A). The SC dose of brazikumab will be administered to all responders/completers in the lead-in study regardless of the prior treatment administered.
Brazikumab Induction Dose
Participants in the lead-in study D5272C00001 (Legacy #3151-201-008) who have not responded to treatment and have met criteria for rescue treatment are considered inadequate/non-responders (Group B). In these eligible participants, IV induction dosing of brazikumab at Week 0, Week 4, and Week 8 will be administered, followed by brazikumab administered subcutaneously every 4 weeks thereafter (up to Week 52).
Research Site, Cape Town
Research Site, Cape Town
Research Site, Plumstead
Research Site, Taipei
Research Site, Rho
Research Site, Milan
Research Site, Hamburg
Research Site, Kiel
Research Site, Wŏnju
Research Site, Miami Lakes
Research Site, Miami
Research Site, Lakeland
Research Site, Taichung
Research Site, Beachwood
Research Site, Evansville
Research Site, Oklahoma City
Research Site, Humble
Research Site, Colorado Springs
Research Site, Ulm
Research Site, Chula Vista
Research Site, Lancaster
Research Site, Haifa
Research Site, Jerusalem
Research Site, České Budějovice
Research Site, Ostrava
Research Site, Roma
Research Site, Kasama-shi
Research Site, Kashiwa-shi
Research Site, Minatoku
Research Site, Krakow
Research Site, Rzeszów
Research Site, Sopot
Research Site, Torun
Research Site, Warsaw
Research Site, Warsaw
Research Site, San Juan
Lead Sponsor
AstraZeneca
INDUSTRY